--- title: "Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers | Sutter Health" description: "Breast Cancer Survival Defined by the ER/PR/HER2" url: "https://www.sutterhealth.org/research/publications/breast-cancer-survival-defined-by-the-er-pr-her2-1055312621" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Research publications](https://www.sutterhealth.org/research/publications) / 4. Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers # Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers. Parise CA & Caggiano V. J Cancer Epidemiol. 2014;2014:469251. doi: 10.1155/2014/469251. Epub 2014 May 26 _Breast Journal_ 2014-05-26 ## Abstract Introduction. ER, PR, and HER2 are routinely available in breast cancer specimens. The purpose of this study is to contrast breast cancer-specific survival for the eight ER/PR/HER2 subtypes with survival of an immunohistochemical surrogate for the molecular subtype based on the ER/PR/HER2 subtypes and tumor grade. Methods. We identified 123,780 cases of stages 1-3 primary female invasive breast cancer from California Cancer Registry. The surrogate classification was derived using ER/PR/HER2 and tumor grade. Kaplan-Meier survival analysis and Cox proportional hazards modeling were used to assess differences in survival and risk of mortality for the ER/PR/HER2 subtypes and surrogate classification within each stage. Results. The luminal B/HER2- surrogate classification had a higher risk of mortality than the luminal B/HER2+ for all stages of disease. There was no difference in risk of mortality between the ER+/PR+/HER2- and ER+/PR+/HER2+ in stage 3. With one exception in stage 3, the ER-negative subtypes all had an increased risk of mortality when compared with the ER-positive subtypes. Conclusions. Assessment of survival using ER/PR/HER2 illustrates the heterogeneity of HER2+ subtypes. The surrogate classification provides clear separation in survival and adjusted mortality but underestimates the wide variability within the subtypes that make up the classification. [PubMed abstract](http://www.ncbi.nlm.nih.gov/pubmed/24955090) ## Research topics - [All Cancer](https://www.sutterhealth.org/research-search-results?query=%22%5C%22All+Cancer%5C%22%22) ## Related publications [View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication) - Publication ### [Light at night and health: the perils of rotating shift work.](https://www.sutterhealth.org/research/publications/light-at-night-perils-of-rotating-shifts-1055312837) Schernhammer ES, Thompson CA. Occup Environ Med. 68(5):310-1. doi: 10.1136/oem.2010.058222. Epub 2010 Oct 4. 2011 May 01 - Publication ### [Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.](https://www.sutterhealth.org/research/publications/phase-ii-trial-of-sequential-therapy-1055312593) Am J Hematol. 2002 Jul;70(3):181-5. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas. Rohatgi N1, LaRocca RV, Bard V, Sethuraman G, Foon KA. Am J Hematol. 2002 Jul;70(3):181-5. 2002 Jul 20 - Publication ### [Meta-analysis in asymmetric catalysis. Influence of chelate geometry on the roles of PN chelating ligands.](https://www.sutterhealth.org/research/publications/meta-analysis-in-asymmetric-catalysis-influence-o-1055312709) Org Biomol Chem. 2013 Jul 28;11(28):4591-601. doi: 10.1039/c3ob40360b. Epub 2013 May 2. Meta-analysis in asymmetric catalysis. Influence of chelate geometry on the roles of PN chelating ligands. Carroll MP1, Guiry PJ, Brown JM. Author information 1School of Chemistry and Chemical Biology, Centre for Synthesis and Chemical Biology, University College Dublin, Dublin 4, Ireland. Org Biomol Chem. 2013 Jul 28;11(28):4591-601. doi: 10.1039/c3ob40360b. Epub 2013 May 2. Meta-analysis in asymmetric catalysis. Influence of chelate geometry on the roles of PN chelating ligands. Carroll MP1 Guiry PJ Brown JM. Author information 1School of Chemistry and Chemical Biology Centre for Synthesis and Chemical Biology University College Dublin Dublin 4 Ireland. 2013 Jul 28 - Publication ### [Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California](https://www.sutterhealth.org/research/publications/breast-cancer-subtypes-as-defined-by-the-estrogen-1055312635) 1999-2004. Breast J. November/December 2009;15(6):593-602. Breast Journal 2009 Dec 20 - Publication ### [Disparities in receipt of adjuvant radiation therapy after breast-conserving surgery among the cancer-reporting regions of California.](https://www.sutterhealth.org/research/publications/disparities-in-receipt-of-adjuvant-radiation-1055312768) 2012 May 1;118(9):2516-24. doi: 10.1002/cncr.26542. Epub 2011 Sep 14. Disparities in receipt of adjuvant radiation therapy after breast-conserving surgery among the cancer-reporting regions of California. Cancer 2011 Sep 14 [View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/publications/breast-cancer-survival-defined-by-the-er-pr-her2-1055312621#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Research publications","item":"https://www.sutterhealth.org/research/publications"},{"@type":"ListItem","position":4,"name":"Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalScholarlyArticle","@id":"https://www.sutterhealth.org/research/publications/breast-cancer-survival-defined-by-the-er-pr-her2-1055312621#medicalscholarlyarticle","name":"Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers","headline":"Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers","abstract":"Introduction. ER, PR, and HER2 are routinely available in breast cancer specimens. The purpose of this study is to contrast breast cancer-specific survival for the eight ER/PR/HER2 subtypes with survival of an immunohistochemical surrogate for the molecular subtype based on the ER/PR/HER2 subtypes and tumor grade. Methods. We identified 123,780 cases of stages 1-3 primary female invasive breast cancer from California Cancer Registry. The surrogate classification was derived using ER/PR/HER2 and tumor grade. Kaplan-Meier survival analysis and Cox proportional hazards modeling were used to assess differences in survival and risk of mortality for the ER/PR/HER2 subtypes and surrogate classification within each stage. Results. The luminal B/HER2- surrogate classification had a higher risk of mortality than the luminal B/HER2+ for all stages of disease. There was no difference in risk of mortality between the ER+/PR+/HER2- and ER+/PR+/HER2+ in stage 3. With one exception in stage 3, the ER-negative subtypes all had an increased risk of mortality when compared with the ER-positive subtypes. Conclusions. Assessment of survival using ER/PR/HER2 illustrates the heterogeneity of HER2+ subtypes. The surrogate classification provides clear separation in survival and adjusted mortality but underestimates the wide variability within the subtypes that make up the classification.","description":"Breast Cancer Survival Defined by the ER/PR/HER2","keywords":["All Cancer"],"datePublished":"2014-05-26","url":"https://www.sutterhealth.org/research/publications/breast-cancer-survival-defined-by-the-er-pr-her2-1055312621","inLanguage":"en-US","identifier":[{"@type":"PropertyValue","propertyID":"PMID","value":"24955090"}],"sameAs":["https://pubmed.ncbi.nlm.nih.gov/24955090/"],"isPartOf":{"@type":"Periodical","name":"Breast Journal"},"sourceOrganization":{"@type":"MedicalOrganization","name":"Sutter Institute for Medical Research"},"about":[{"@type":"DefinedTerm","name":"All Cancer","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22All+Cancer%22%5D%7D%5D&verticalKey=research_publication"}],"mainEntityOfPage":{"@type":"WebPage","@id":"https://www.sutterhealth.org/research/publications/breast-cancer-survival-defined-by-the-er-pr-her2-1055312621","breadcrumb":{"@id":"https://www.sutterhealth.org/research/publications/breast-cancer-survival-defined-by-the-er-pr-her2-1055312621#breadcrumblist"}}} ```